Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
PG2 has been approved in Taiwan to treat cancer-related fatigue for advanced cancer patients.
The primary objective of this study is to evaluate the efficacy of PG2 on fatigue relief in
patients undergoing palliative abdominal surgery for cancer. The secondary endpoints,
including the length of hospital stay, postoperative complications, HRQL, inflammatory
biomarkers, the duration of antibiotic therapy, mortality during the hospital stay, weight
loss and body composition, will be evaluated among these patients.